Related Experiment Videos
Partial proteolysis of human L-type phosphofructokinase.
Enzyme
|January 1, 1981
Summary
Human leukocyte phosphofructokinase subunits are lighter than those from liver and red blood cells. Subtilisin treatment of red blood cell enzyme mimics this change and reduces allosteric properties.
Area of Science:
- Biochemistry
- Molecular Biology
- Enzymology
Background:
- Phosphofructokinase (PFK) is a key glycolytic enzyme.
- Different PFK subunit types exist, including the L (liver) type.
- Investigating PFK subunit variations can reveal insights into enzyme regulation.
Purpose of the Study:
- To compare the molecular weight of L-type phosphofructokinase subunits from human leukocytes with those from liver and red blood cells.
- To investigate the effect of subtilisin treatment on red blood cell L4 phosphofructokinase subunits and its kinetic properties.
Main Methods:
- Purification of L-type phosphofructokinase subunits from human leukocytes.
- Mild enzymatic treatment of red blood cell L4 enzyme using subtilisin.
- Molecular weight determination of enzyme subunits.
- Kinetic analysis of enzyme allosteric properties.
Main Results:
- Leukocyte L-type phosphofructokinase subunits exhibit a slightly lower molecular weight compared to liver and red blood cell subunits.
- Subtilisin treatment of red blood cell L4 phosphofructokinase results in subunits with molecular weights similar to leukocyte forms.
- Both subtilisin-treated red blood cell enzyme and leukocyte enzyme show diminished allosteric properties compared to untreated red blood cell L4 phosphofructokinase.
Conclusions:
- Human leukocyte L-type phosphofructokinase subunits possess distinct molecular characteristics.
- Enzymatic modification can alter PFK subunit structure and consequently affect its allosteric regulation.
- These findings contribute to understanding the structural and functional diversity of phosphofructokinase in human tissues.